Mylan

Biocon received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia.

According to reports, Mylan, which is part of Viatris, planned to sell up to 5.64 per cent stake in Biocon, worth up to ₹3,481 crore in block deals today.

Mylan, part of global healthcare company Viatris, plans to sell up to 92 million shares in Biocon through a secondary offering valued at as much as Rs 34.81 billion

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, a report said

Biocon said its arm, Biocon Biologics, and Mylan have been informed by the USFDA of a deferred action on the biologics license application for a biosimilar to drug Avastin

The commercialisation in the US of the drug, which already has approval in 45 countries, gives a boost to Biocon's ambitious target of $1 billion in sales through its biologics division by FY22

Domestic players will be free to price it; Dutch firm Mylan also to make the drug in India; no royalty for Gilead as yet

CEO of Biocon Biologics, Dr Christiane Hamacher said, Fulphila, co-developed by Biocon Biologics and Mylan, is the third biosimilar to be commercialised in Australia

Firm seen benefiting from operating leverage, biologic sales by FY22

In the second part of a series, the author notes down some lessons for start-ups

Development takes Biocon a step closer to commercialise its glargine biosimilar Semglee in America

The application seeks approval of biosimilar bevacizumab for treatment of patients with metastatic colorectal cancer in addition to other ailments

The application seeks approval of Bevacizumab for the first-line and second-line treatment of patients with metastatic colorectal cancer in combination with fluorouracil-based chemotherapy

Even as the Street will monitor product ramp-up, commercialisation of more biosimilars will drive prospects further

Ogivri will be launched at a competitive discount for customers to help ensure access and increase treatment options for patients

Separation of Pfizer's off-patent business would be a tax-free spin-off

Homegrown firms saw R&D spend, as percentage of sales, rise in past 5 years

BS ReporterHyderabad, 6 September: American generics drug major Mylan is looking for a buyer for its formulations manufacturing facility in Vizag Pharma City for some business considerations. While there was no official conformation either on the decision or the reasons behind it from Mylan's Indian subsidiary, sources aware of the matter said the plant has been on the block for some time now.Entered India ten years ago on the back of its maiden acquisition of Hyderabad-based Matrix Laboratories in 2007, Mylan has built a huge global manufacturing base in the country, mostly through inorganic route, since then. 25 out of its 40 manufacturing facilities as well as one of the three global R&D centers of the company are located in India.Mylan had acquired Vizag facility in 2012 from Hyderabad-based SMS Pharma for $ 32.5 million. SMS Pharma had built this plant for products related to cancer therapy.While there are no concrete details available on why Mylan wants to dispose of this ..

The pharma firm also failed to establish an adequate quality control unit